ArQule to Report Third Quarter 2019 Financial Results on October 30, 2019
October 16 2019 - 7:00AM
Business Wire
ArQule, Inc. (Nasdaq: ARQL) today announced it will report
financial results for the third quarter of 2019 before the market
opens on Wednesday, October 30, 2019. The Company will hold a
conference call and webcast on the same day at 9:00 a.m. ET to
discuss these results and provide a general business update.
The live webcast can be accessed in the “Investors and Media”
section of our website, www.arqule.com, under “Events &
Presentations.” You may also listen to the call by dialing (877)
868-1831 within the U.S. or (914) 495-8595 outside the U.S. and
entering the conference ID: 4289763. A replay will be available two
hours after the completion of the call and can be accessed in the
“Investors & Media” section of our website, www.arqule.com,
under “Events and Presentations.”
About ArQule ArQule is a biopharmaceutical company
engaged in the research and development of targeted therapeutics to
treat cancers and rare diseases. ArQule’s mission is to discover,
develop and commercialize novel small molecule drugs in areas of
high unmet need that will dramatically extend and improve the lives
of our patients. Our clinical-stage pipeline consists of four drug
candidates, all of which are in targeted, biomarker-defined patient
populations, making ArQule a leader among companies our size in
precision medicine. ArQule’s pipeline includes: ARQ 531, an orally
bioavailable, potent and reversible dual inhibitor of both wild
type and C481S-mutant BTK, in phase 1/2 for patients with B-cell
malignancies refractory to other therapeutic options; miransertib
(ARQ 092), a potent and selective inhibitor of the AKT
serine/threonine kinase, in a registrational trial with cohorts in
Proteus syndrome and PROS; ARQ 751, a next generation highly potent
and selective AKT inhibitor, in phase 1 for patients with solid
tumors with AKT1 and PI3K mutations; and derazantinib, a
multi-kinase inhibitor designed to preferentially inhibit the
fibroblast growth factor receptor (FGFR) family, in a
registrational trial for iCCA in collaboration with Basilea and
Sinovant. ArQule’s current discovery efforts are focused on the
identification and development of novel kinase inhibitors,
leveraging the Company’s proprietary library of compounds.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191016005097/en/
Corporate Contact: Kathleen Farren Investor Relations
& Executive Assistant to the CFO ir@arqule.com
Media Contact: Cait Williamson, Ph.D. LifeSci Public
Relations (646) 751-4366 cait@lifescipublicrelations.com
www.ArQule.com
ArQule (NASDAQ:ARQL)
Historical Stock Chart
From Mar 2024 to Apr 2024
ArQule (NASDAQ:ARQL)
Historical Stock Chart
From Apr 2023 to Apr 2024